A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse ChristiansenThomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeer Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H J van Oers, Christian Hartmann Geisler, Stephan Stilgenbauer, Michael Hallek

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
JournalBlood
Volume138
Issue numberSupplement 1
Pages (from-to)71
ISSN0006-4971
DOIs
Publication statusPublished - Nov 2021
Event63rd ASH Annual Meeting. - Georgia World Congress Center and Virtual, Atlanta, United States
Duration: 11. Dec 202114. Dec 2021

Conference

Conference63rd ASH Annual Meeting.
LocationGeorgia World Congress Center and Virtual
Country/TerritoryUnited States
CityAtlanta
Period11/12/202114/12/2021

Cite this